AESIs	Adverse Events of Special Interest
AFP	Acute Flaccid Paralysis
bOPV	Bivalent Oral Polio Vaccine
BPOM	Badan POM (Indonesian Regulatory Authority)
cVDPV	Circulating Vaccine-derived Poliovirus
cVDPV2	Circulating Vaccine-derived Poliovirus type 2
DG	Director-General (of WHO)
DRC	Democratic Republic of the Congo
EUA	Emergency Use Authorization
EUAL	Emergency Use Assessment and Listing
EUL	Emergency Use Listing
GACVS	Global Advisory Committee on Vaccine Safety
GAP	Global Action Plan
GPEI	Global Polio Eradication Initiative
GPLN	Global Polio Laboratory Network
IPV	Inactivated Poliovirus Vaccine
mOPV2	Monovalent Oral Polio Vaccine type 2
MRC	Medical Research Council
NIBSC	National Institute for Biological Standards and Controls
nOPV	Novel Oral Polio Vaccine
nOPV2	Novel Oral Polio Vaccine type 2
nOPV WG	Novel Oral Polio Vaccine Working Group
OPV	Oral Polio Vaccine
OPV2	Oral Polio Vaccine type 2
PQ	Prequalification
PQT	Prequalification Team
SAGE	Strategic Advisory Group of Experts to the WHO
SIAs	Supplementary Immunization Activities
tOPV	Trivalent Oral Polio Vaccine
UNICEF	United Nations Children’s Fund
US CDC	US Centers for Disease Control and Prevention
VAPP	Vaccine-associated Paralytic Poliomyelitis
VDPV	Vaccine-derived Poliovirus
WHO	World Health Organization
WPV2	Wild Poliovirus type 2